AHA
MCID: ANM038
MIFTS: 63

Anemia, Autoimmune Hemolytic (AHA)

Categories: Blood diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Anemia, Autoimmune Hemolytic

MalaCards integrated aliases for Anemia, Autoimmune Hemolytic:

Name: Anemia, Autoimmune Hemolytic 57
Autoimmune Hemolytic Anemia 12 73 20 58 36 29 54 6 15 70
Idiopathic Autoimmune Hemolytic Anemia 20 70
Anemia, Hemolytic, Autoimmune 44 17
Immuno-Hemolytic Anemia 20 70
Familial Auto-Immune Hemolytic Anemia 20
Acquired Autoimmune Hemolytic Anemia 20
Autoimmune Haemolytic Anaemia 12
Autoimmune Hemolytic Anaemia 12
Anemia Hemolytic Autoimmune 20
Aiha 58
Aha 58

Characteristics:

Orphanet epidemiological data:

58
autoimmune hemolytic anemia
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: elderly;

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal recessive


HPO:

31
anemia, autoimmune hemolytic:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:718
OMIM® 57 205700
KEGG 36 H01585
ICD9CM 34 283.0
MeSH 44 D000744
NCIt 50 C34378
SNOMED-CT 67 25121006
MESH via Orphanet 45 D000744
ICD10 via Orphanet 33 D59.0 D59.1
UMLS via Orphanet 71 C0002880
Orphanet 58 ORPHA98375
MedGen 41 C0002880
UMLS 70 C0002880 C0543663 C2931849

Summaries for Anemia, Autoimmune Hemolytic

KEGG : 36 Autoimmune hemolytic anemia (AIHA) is a relatively uncommon disorder caused by the increased destruction of red blood cells (RBCs) by anti-RBC autoantibodies with or without complement activation. AIHAs can be distinguished on the basis of the autoantibody Ig class and thermal characteristics, i.e. the optimal temperature of reaction with autologous erythrocytes, in warm (wAIHA), cold (cold agglutinin disease; CAD), and mixed forms, although atypical cases of difficult diagnostic classification are reported with increasing frequency. Moreover, AIHAs are classified in primary (idiopathic), in which hemolysis dominates the clinical picture in the absence of any other coexisting disorder, and in secondary forms, accompanying and complicating an underlying disease. AIHA may develop gradually, or have a fulminant onset with life-threatening anemia. The diagnosis is usually simple, based on the presence of hemolytic anemia and serological evidence of anti-erythrocyte antibodies, detectable by the direct antiglobulin test (DAT).

MalaCards based summary : Anemia, Autoimmune Hemolytic, also known as autoimmune hemolytic anemia, is related to evans' syndrome and autoimmune lymphoproliferative syndrome, type iia. An important gene associated with Anemia, Autoimmune Hemolytic is SOCS1 (Suppressor Of Cytokine Signaling 1), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Tacrolimus and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and bone marrow, and related phenotypes are muscle weakness and fatigue

Disease Ontology : 12 An autoimmune disease of blood that is characterized by deficient red blood cells caused by auto-antibodies.

GARD : 20 Autoimmune hemolytic anemia (AIHA) occurs when your immune system makes antibodies that attack your red blood cells. This causes a drop in the number of red blood cells, leading to hemolytic anemia. Symptoms may include unusual weakness and fatigue with tachycardia and breathing difficulties, jaundice, dark urine and/or splenomegaly. AIHA can be primary (idiopathic) or result from an underlying disease or medication. The condition may develop gradually or occur suddenly. There are two main types of autoimmune hemolytic anemia : warm antibody hemolytic anemia and cold antibody hemolytic anemia. Treatment may include corticosteroids such as prednisone, splenectomy, immunosuppressive drugs and/or blood transfusions.

Wikipedia : 73 Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood... more...

More information from OMIM: 205700

Related Diseases for Anemia, Autoimmune Hemolytic

Diseases in the Hemolytic Anemia family:

Anemia, Autoimmune Hemolytic Congenital Hemolytic Anemia
Rare Acquired Hemolytic Anemia Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction
Hemolytic Anemia Due to an Erythrocyte Nucleotide Metabolism Disorder Hemolytic Anemia Due to a Disorder of Glycolytic Enzymes
Hemolytic Anemia Due to Hexose Monophosphate Shunt and Glutathione Metabolism Anomalies Rare Hemolytic Anemia

Diseases related to Anemia, Autoimmune Hemolytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 919)
# Related Disease Score Top Affiliating Genes
1 evans' syndrome 32.3 LRBA HP CTLA4 CD4 CCR6
2 autoimmune lymphoproliferative syndrome, type iia 32.2 CD8A CD4
3 autoimmune lymphoproliferative syndrome 31.8 LRBA ICOSLG CTLA4 CD8A CD4 CD19
4 common variable immunodeficiency 31.8 LRBA ICOSLG CTLA4 CD40LG CD19
5 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 31.5 LRBA ICOSLG CTLA4 CD8A CD4 CCR6
6 hemoglobinuria 31.3 HP G6PD CD59 CD55 C3
7 agammaglobulinemia 31.3 ICOSLG CD40LG CD19
8 thrombocytopenic purpura, autoimmune 31.1 SOCS1 LRBA ICOSLG CD4 CCR6
9 glomerulonephritis 31.0 CD55 CD40LG C3 C1S
10 colitis 31.0 SOCS1 ICOSLG CTLA4 CD4 CCR6
11 hepatitis a 30.9 GYPA CTLA4 CD4
12 lupus erythematosus 30.9 SOCS1 CTLA4 CD40LG C3 C1S
13 autoimmune disease 30.9 ICOSLG CTLA4 CD55 CD40LG CCR6 C3
14 paroxysmal nocturnal hemoglobinuria 30.9 HP CD59 CD55 C3
15 thrombocytopenia due to platelet alloimmunization 30.8 SOCS1 ICOSLG CD8A CD4 CD19 CCR6
16 cholangitis, primary sclerosing 30.8 ICOSLG CD8A CD4 CCR6
17 cryoglobulinemia, familial mixed 30.8 CD5 CD40LG
18 sarcoidosis 1 30.8 ICOSLG CD8A CD4 CCR6
19 bilirubin metabolic disorder 30.7 RHCE HP G6PD CD8A CD4
20 marginal zone b-cell lymphoma 30.7 CD5 CD40LG CD19 CCR6 C1S
21 pancytopenia 30.7 HP CD8A CD55 CD5 CD4 CD19
22 connective tissue disease 30.7 ICOSLG CD8A CD40LG CD4 CCR6
23 cellulitis 30.7 CD8A CD4 CCR6
24 pfeiffer syndrome 30.7 CD8A CD40LG CD4 CD19 CCR6
25 exanthem 30.7 ICOSLG CTLA4 CD8A CD4 CCR6
26 b cell prolymphocytic leukemia 30.7 CD5 CD19
27 vasculitis 30.7 CTLA4 CD40LG C3 C1S
28 plasmodium falciparum malaria 30.6 HP G6PD CD55
29 primary biliary cholangitis 30.6 SOCS1 ICOSLG CTLA4 CD8A CD40LG CD4
30 respiratory failure 30.6 G6PD CD8A CD4 CCR6
31 lymphopenia 30.6 CTLA4 CD59 CD55
32 syphilis 30.6 CD8A CD40LG CD4 CCR6
33 crohn's disease 30.6 ICOSLG HP CTLA4 CD4 CCR6
34 leukemia, chronic lymphocytic 30.6 ICOSLG CTLA4 CD8A CD59 CD55 CD5
35 cll/sll 30.5 CD5 CD19 CCR6
36 hemolytic-uremic syndrome 30.5 HP CD55 C3
37 vitiligo-associated multiple autoimmune disease susceptibility 1 30.5 ICOSLG CTLA4 CD8A CD4 CCR6
38 systemic scleroderma 30.4 ICOSLG CD8A CD40LG CD4 CCR6
39 immune deficiency disease 30.4 ICOSLG CTLA4 CD8A CD5 CD40LG CD4
40 parotitis 30.4 G6PD CD8A CD4
41 common cold 30.4 ICOSLG CD4 CCR6
42 neuromyelitis optica 30.4 CD59 CD40LG C3
43 viral pneumonia 30.3 CD8A CD4 CCR6
44 lymphoplasmacytic lymphoma 30.3 CD5 CD40LG CD19
45 complement deficiency 30.3 CD55 C3 C1S
46 histoplasmosis 30.3 CD4 CCR6 C3
47 acquired angioedema 30.3 HP C3 C1S
48 myeloma, multiple 30.3 ICOSLG CTLA4 CD8A CD5 CD4 CD19
49 lymphadenitis 30.3 SOCS1 ICOSLG CD4 CCR6
50 hemoglobinopathy 30.3 RHCE HP GYPA G6PD

Comorbidity relations with Anemia, Autoimmune Hemolytic via Phenotypic Disease Network (PDN):


Acquired Thrombocytopenia Acute Cystitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Leukemia, Chronic Lymphocytic
Neutropenia

Graphical network of the top 20 diseases related to Anemia, Autoimmune Hemolytic:



Diseases related to Anemia, Autoimmune Hemolytic

Symptoms & Phenotypes for Anemia, Autoimmune Hemolytic

Human phenotypes related to Anemia, Autoimmune Hemolytic:

58 31 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001324
2 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
3 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
4 hemolytic anemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001878
5 dyspnea 58 31 hallmark (90%) Very frequent (99-80%) HP:0002094
6 headache 58 31 hallmark (90%) Very frequent (99-80%) HP:0002315
7 abnormal leukocyte morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0001881
8 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
9 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
10 lymphoma 58 31 frequent (33%) Frequent (79-30%) HP:0002665
11 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
12 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
13 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
14 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
15 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
16 abnormal urinary color 58 31 occasional (7.5%) Occasional (29-5%) HP:0012086
17 abnormality of metabolism/homeostasis 31 HP:0001939
18 autoimmune hemolytic anemia 31 HP:0001890

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Heme:
autoimmune hemolytic anemia

Lab:
coombs positive
abnormal immunoglobulin in heterozygotes

Clinical features from OMIM®:

205700 (Updated 05-Apr-2021)

GenomeRNAi Phenotypes related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.6 CD40LG CD59
2 Decreased viability GR00249-S 9.6 CD19 G6PD HP SOCS1 STIM2
3 Decreased viability GR00342-S-2 9.6 CD4
4 Decreased viability GR00381-A-1 9.6 CD19 RHCE
5 Decreased viability GR00381-A-3 9.6 RHCE
6 Decreased viability GR00386-A-1 9.6 C3 CD5 G6PD GYPA ICOSLG RHCE
7 Decreased viability GR00402-S-2 9.6 CD8A G6PD

MGI Mouse Phenotypes related to Anemia, Autoimmune Hemolytic:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 C3 CCR6 CD19 CD4 CD40LG CD5
2 immune system MP:0005387 9.77 C3 CCR6 CD19 CD4 CD40LG CD5
3 renal/urinary system MP:0005367 9.23 C3 CD19 CD40LG CD55 CD59 CD8A

Drugs & Therapeutics for Anemia, Autoimmune Hemolytic

Drugs for Anemia, Autoimmune Hemolytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
2 Immunologic Factors Phase 4
3 Immunosuppressive Agents Phase 4
4 Calcineurin Inhibitors Phase 4
5
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
6
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
7
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
8
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
9
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
10
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
11
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
12
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
13 Neuroprotective Agents Phase 3
14 Methylprednisolone Acetate Phase 3
15 Antineoplastic Agents, Immunological Phase 3
16 Antirheumatic Agents Phase 3
17 Protective Agents Phase 3
18 Antineoplastic Agents, Hormonal Phase 3
19 glucocorticoids Phase 3
20 Anti-Inflammatory Agents Phase 3
21 Immunoglobulins Phase 3
22 Antibodies Phase 3
23 Autoantibodies Phase 3
24 Pharmaceutical Solutions Phase 3
25 Agglutinins Phase 3
26
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 2 14769-73-4 26879
27
Lenograstim Approved, Investigational Phase 2 135968-09-1
28
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
29
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
30
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
31
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
32
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
33
Lactitol Approved, Investigational Phase 1, Phase 2 585-86-4 157355
34
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
35
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
36
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
37
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 6436030 5284616
38
Acyclovir Approved Phase 2 59277-89-3 2022
39
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
40
Montelukast Approved Phase 1, Phase 2 158966-92-8 5281040
41
Promethazine Approved, Investigational Phase 1, Phase 2 60-87-7 4927
42
Acetaminophen Approved Phase 1, Phase 2 103-90-2 1983
43
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6, 75614-87-8 774
44
Famotidine Approved Phase 1, Phase 2 76824-35-6 3325
45
Diphenhydramine Approved, Investigational Phase 1, Phase 2 58-73-1, 147-24-0 3100
46
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
47 Adjuvants, Immunologic Phase 2
48 Antiparasitic Agents Phase 2
49 Anthelmintics Phase 2
50 Alkylating Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Tacrolimus Treatment for Refractory Autoimmune Cytopenia Recruiting NCT03918265 Phase 4 Tacrolimus
2 Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial. Completed NCT01134432 Phase 3 prednisolone + mabthera;Prednisolone
3 Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial Completed NCT01181154 Phase 3 rituximab (Mabthera®);Placebo
4 Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias Completed NCT00749112 Phase 2, Phase 3 Alemtuzumab, Rituximab
5 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Recruiting NCT03764618 Phase 3 Fostamatinib disodium;Placebo
6 Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label Extension Recruiting NCT04119050 Phase 2, Phase 3 M281;Placebo
7 A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Active, not recruiting NCT04138927 Phase 3 Fostamatinib disodium
8 A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion Active, not recruiting NCT03347396 Phase 3 Sutimlimab
9 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion Active, not recruiting NCT03347422 Phase 3 sutimlimab (BIVV009);placebo
10 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
11 Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease Completed NCT00010387 Phase 2 cyclophosphamide;filgrastim
12 A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia Completed NCT01345708 Phase 2 prednisone, low dose rituximab
13 " Anemil Trial ": Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment Completed NCT02389231 Phase 1, Phase 2 Interleukine-2
14 CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) Completed NCT00309881 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
15 Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series Completed NCT00392951 Phase 1, Phase 2 sirolimus
16 Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine. Completed NCT00373594 Phase 2 Rituximab;Fludarabine
17 Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab Completed NCT01303952 Phase 2 Eculizumab
18 Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease Completed NCT01696474 Phase 2 Bortezomib
19 The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy Completed NCT02689986 Phase 2 Bendamustine, Rituximab
20 A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia Recruiting NCT03538041 Phase 2 Parsaclisib
21 A Phase II, Single-Center, Open-label Trial to Determine the Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Recruiting NCT04398459 Phase 2 Ibrutinib
22 An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia Recruiting NCT04083014 Phase 2 combination of a single dose anti-CD20 antibody and bortezomib
23 A Phase 2 Trial of Acalabrutinib for the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia Recruiting NCT04657094 Phase 2 Acalabrutinib
24 Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment Approach Active, not recruiting NCT03827603 Phase 2 Ibrutinib
25 An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) Active, not recruiting NCT03226678 Phase 2 APL-2
26 A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Active, not recruiting NCT02612558 Phase 2 Fostamatinib 150 mg bid
27 A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA) Not yet recruiting NCT04691570 Phase 2 ANX005
28 A Multicenter, Open-label, Non-randomized, Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia Not yet recruiting NCT04661033 Phase 1, Phase 2 Isatuximab SAR650984;Diphenhydramine;Famotidine;Acetaminophen;Montelukast
29 A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia Suspended NCT04253236 Phase 2 RVT-1401 680 mg/weekly;RVT-1401 340 mg/weekly
30 A Phase 1B/2, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA) Terminated NCT03075878 Phase 1, Phase 2 ALXN1830
31 A Phase 2 Randomized, Dose-blind, Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP) Withdrawn NCT04039477 Phase 2 KZR-616
32 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia Withdrawn NCT04256148 Phase 2
33 A Prospective Open-label Trial to Assess the Efficacy and Safety of Ixazomib and Dexamethasone in Patients With Refractory Autoimmune Cytopenia Withdrawn NCT03965624 Phase 2 Ninlaro
34 High-Dose Cyclophosphamide With CD34+ Selected Autologous Hematopoietic Cell Support for Treatment of Refractory Chronic Autoimmune Thrombocytopenia Completed NCT00001630 Phase 1
35 A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease Recruiting NCT04269551 Phase 1 BIVV020
36 An Open Label, Long Term, Safety and Tolerability Study of Patients With Cold Agglutinin Disease Previously Treated With BIVV020 Recruiting NCT04802057 Phase 1 BIVV020
37 Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study. Active, not recruiting NCT02502903 Phase 1 BIV009
38 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
39 Immunopathology of Autoimmune Hemolytic Anemia: an Open, Prospective and Multicenter Study Unknown status NCT02158195
40 Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia in Assiut University Hospital Completed NCT03269292
41 The RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune Disorders Completed NCT00960713 Rituximab (MABTHERA® or RITUXAN®).
42 National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia Completed NCT04070612
43 National Study Backed by a Rare Disease Cohort the Benefit / Risk Balance of Immunomodulatory Treatments Prescribed in the Child and Adolescent for Autoimmune Cytopenia. Completed NCT04057703
44 Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA) Recruiting NCT02828670
45 The DRAIHA Study: Data Registry of AutoImmune Hemolytic Anemia, to Improve Diagnostic Testing for the Development of Personalized Treatment Protocols in AIHA Patients Recruiting NCT04024202
46 Register für Schwere Immunzytopenien - Severe Immune Cytopenia Registry (SIC-Reg.Org) Recruiting NCT03576742
47 Autoimmune Cytopenias : Midi-Pyrenees Registry Recruiting NCT02877706
48 Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia Recruiting NCT04005638
49 Umbilical Cord Blood Treatment for Refractory Immune Cytopenia: a Single-arm Prospective Study Recruiting NCT04420494
50 The Significance of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Not yet recruiting NCT04814394

Search NIH Clinical Center for Anemia, Autoimmune Hemolytic

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cyclophosphamide
Immunoglobulins, Intravenous

Cochrane evidence based reviews: anemia, hemolytic, autoimmune

Genetic Tests for Anemia, Autoimmune Hemolytic

Genetic tests related to Anemia, Autoimmune Hemolytic:

# Genetic test Affiliating Genes
1 Autoimmune Hemolytic Anemia 29

Anatomical Context for Anemia, Autoimmune Hemolytic

MalaCards organs/tissues related to Anemia, Autoimmune Hemolytic:

40
Liver, Bone, Bone Marrow, Kidney, B Cells, Heart, Spleen

Publications for Anemia, Autoimmune Hemolytic

Articles related to Anemia, Autoimmune Hemolytic:

(show top 50) (show all 3217)
# Title Authors PMID Year
1
[Familial autoimmune hemolytic animia (AIHA) with negative Coombs test, lymphocytopenia and hypogammaglobulinemia]. 57 61
1209224 1975
2
Hereditary aspects of autoimmune hemolytic anemia; a retrospective analysis. 61 57
5660845 1968
3
Familial autoimmune haemolytic anaemia. 57
861649 1977
4
FAMILIAL AUTO-IMMUNE HEMOLYTIC ANEMIA. 57
14315660 1965
5
"ACQUIRED" ANTIBODY HEMOLYTIC ANEMIA AND FAMILIAL ABERRATIONS IN GAMMA GLOBULINS. 57
14124686 1964
6
Immuno-hemolytic anemia with familial occurence. 57
13007407 1952
7
Low concentration of serum haptoglobin has impact on understanding complex pathophysiology in patients with acquired bone marrow failure syndromes. 54 61
20376581 2010
8
Severe autoimmune hemolytic anemia associated with IgM warm auto-antibodies in primary Sjögren's syndrome. 61 54
20374393 2010
9
Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. 61 54
18980619 2009
10
[Density-specific distribution of erythrocytes in different types of anemia]. 54 61
19253711 2009
11
Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia. 54 61
18954403 2009
12
Etiology of hemolysis in two patients with hepatitis A infection: glucose-6-phosphate dehydrogenase deficiency or autoimmune hemolytic anemia. 54 61
18320220 2008
13
The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. 61 54
17289551 2007
14
Aortic valve replacement for a patient with glucose-6-phosphate dehydrogenase deficiency and autoimmune hemolytic anemia. 54 61
15985145 2005
15
Experience with eosin-5'-maleimide as a diagnostic tool for red cell membrane cytoskeleton disorders. 61 54
14641141 2003
16
Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. 54 61
12728121 2003
17
Quantitation of red cell-bound IgG, IgA, and IgM in patients with autoimmune hemolytic anemia and blood donors by enzyme-linked immunosorbent assay. 61 54
15373694 2003
18
Regulation of the immune response by natural IgM: lessons from warm autoimmune hemolytic anemia. 54 61
12871191 2003
19
[Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria]. 61 54
11930678 2001
20
[Application of the gel test using and anti-IgA antiglobulin for the immunologic diagnosis of autoimmune hemolytic anemia with a negative direct Coombs test]. 61 54
10472686 1999
21
Fatal autoimmune hemolytic anemia in a child due to warm-reactive immunoglobulin M antibody. 54 61
9787330 1998
22
Erythrocyte membrane proteins reactive with IgG (warm-reacting) anti-red blood cell autoantibodies: II. Antibodies coprecipitating band 3 and glycophorin A. 61 54
7517724 1994
23
Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases. 61
33594951 2021
24
Common Variable Immunodeficiency, Autoimmune Hemolytic Anemia, and Pancytopenia Associated With a Defect in IKAROS. 61
33122583 2021
25
Refractory and Fatal Presentation of Severe Autoimmune Hemolytic Anemia in a Child With the DNASE1L3 Mutation Complicated With an Additional DOCK8 Variant. 61
32205782 2021
26
Acute Kidney Injury Caused by Evans Syndrome with Systemic Lupus Erythematosus and Systemic Sclerosis. 61
33116016 2021
27
Erythrophagocytosis by monocytes: An unusual observation in autoimmune hemolytic anemia. 61
32808673 2021
28
Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report. 61
33625086 2021
29
How I treat warm autoimmune hemolytic anemia. 61
33512406 2021
30
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma. 61
33752275 2021
31
Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia? 61
33750754 2021
32
Autoimmune Complications in Hematologic Neoplasms. 61
33810369 2021
33
Massive intrasplenic arterial thrombosis in a patient with chronic ITP during the development of an Evans syndrome. 61
33714615 2021
34
Ovarian and non-ovarian teratomas: a wide spectrum of features. 61
32875471 2021
35
The impact of autoimmune cytopenias on the clinical course and survival of Hodgkin lymphoma. 61
33057959 2021
36
Patterns of Immune Dysregulation in Primary Immunodeficiencies: A Systematic Review. 61
33186766 2021
37
Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases. 61
33544201 2021
38
Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia. 61
31533519 2021
39
Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL. 61
32548659 2021
40
COVID-19 associated with severe autoimmune hemolytic anemia. 61
33274459 2021
41
Clinical Profile and Outcome of Childhood Autoimmune Hemolytic Anemia: A Single Center Study. 61
33634793 2021
42
Severe warm autoimmune hemolytic anemia in COVID-19 managed with least incompatible RBC product and glucocorticoids. 61
33604688 2021
43
Severe IgA-mediated autoimmune hemolytic anemia triggered by SARS-CoV-2 infection. 61
33618609 2021
44
Prednisolone-responsive primary sclerosing cholangitis with autoimmune hemolytic anemia: a case report and review of the literature. 61
33038000 2021
45
A novel zeta-associated protein 70 homozygous mutation causing combined immunodeficiency presenting as neonatal autoimmune hemolytic anemia. 61
33484432 2021
46
Autoimmune hemolytic anemia complicated by parvovirus infection. 61
33630052 2021
47
Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study. 61
32354865 2021
48
[An updated advance of autoimmune hepatitis in children]. 61
33541017 2021
49
[The clinical manifestations and risk factors in primary antiphospholipid syndrome with thrombocytopenia]. 61
33677866 2021
50
Nocardia kroppenstedtii: a rare pathogen isolated from the spinal vertebral abscess of a patient on long-term immunosuppressive therapy. 61
33577013 2021

Variations for Anemia, Autoimmune Hemolytic

ClinVar genetic disease variations for Anemia, Autoimmune Hemolytic:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SOCS1 NM_003745.1(SOCS1):c.24del (p.Ala9fs) Deletion Likely pathogenic 977213 GRCh37: 16:11349312-11349312
GRCh38: 16:11255455-11255455
2 SOCS1 NM_003745.1(SOCS1):c.476_480dup (p.Met161fs) Microsatellite Likely pathogenic 977214 GRCh37: 16:11348855-11348856
GRCh38: 16:11254998-11254999

Expression for Anemia, Autoimmune Hemolytic

Search GEO for disease gene expression data for Anemia, Autoimmune Hemolytic.

Pathways for Anemia, Autoimmune Hemolytic

Pathways related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 SOCS1 ICOSLG HP CTLA4 CD8A CD59
2
Show member pathways
13.3 SOCS1 ICOSLG CTLA4 CD8A CD40LG CD4
3
Show member pathways
12.54 ICOSLG CTLA4 CD8A CD55 CD40LG CD4
4 12.37 SOCS1 CTLA4 CD8A CD40LG CD19
5
Show member pathways
12.24 ICOSLG CTLA4 CD40LG CD4
6
Show member pathways
12.01 CD59 CD55 C3 C1S
7
Show member pathways
11.96 CD59 CD55 C3 C1S
8 11.94 CD59 CD55 C3 C1S
9 11.89 ICOSLG CTLA4 CD8A CD40LG CD4
10 11.86 CD8A CD40LG CD19 C3
11
Show member pathways
11.66 CD55 C3 C1S
12 11.65 CD8A CD4 CCR6
13 11.59 CD8A CD4 CD19
14 11.56 CTLA4 CD8A CD4
15 11.5 GYPA CD8A CD59 CD5 CD4 CD19
16 11.49 ICOSLG CTLA4 CD40LG CCR6
17 11.16 GYPA CD8A CD59 CD55 CD5 CD4
18 11.04 CD8A CD40LG CD4 CD19

GO Terms for Anemia, Autoimmune Hemolytic

Cellular components related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.22 STIM2 RHCE LRBA ICOSLG GYPA GET1
2 integral component of membrane GO:0016021 10.18 STIM2 RHCE LRBA ICOSLG GYPA GET1
3 plasma membrane GO:0005886 10 STIM2 LRBA ICOSLG GYPA CTLA4 CD8A
4 cell surface GO:0009986 9.73 CD59 CD55 CD40LG CD4 CCR6 C3
5 integral component of plasma membrane GO:0005887 9.61 RHCE GYPA CTLA4 CD8A CD5 CD40LG
6 external side of plasma membrane GO:0009897 9.23 ICOSLG CTLA4 CD8A CD5 CD40LG CD4

Biological processes related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.83 ICOSLG CTLA4 CD8A CD4 CD19
2 immune response GO:0006955 9.73 CTLA4 CD8A CD40LG CD4 CCR6 C3
3 regulation of immune response GO:0050776 9.71 CD8A CD40LG CD19 C3
4 T cell activation GO:0042110 9.5 ICOSLG CD8A CD4
5 T cell costimulation GO:0031295 9.46 ICOSLG CTLA4 CD5 CD40LG
6 regulation of complement-dependent cytotoxicity GO:1903659 9.37 CD59 CD55
7 regulation of complement activation GO:0030449 9.35 CD59 CD55 CD19 C3 C1S
8 immune system process GO:0002376 9.28 ICOSLG HP CTLA4 CD8A CD55 CD4

Molecular functions related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 STIM2 SOCS1 LRBA ICOSLG HP GYPA
2 virus receptor activity GO:0001618 8.8 GYPA CD55 CD4

Sources for Anemia, Autoimmune Hemolytic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....